First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Children
Top Cited Papers
Open Access
- 17 November 2011
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 365 (20), 1863-1875
- https://doi.org/10.1056/nejmoa1102287
Abstract
An ongoing phase 3 study of the efficacy, safety, and immunogenicity of candidate malaria vaccine RTS,S/AS01 is being conducted in seven African countries.Keywords
This publication has 23 references indexed in Scilit:
- Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trialThe Lancet Infectious Diseases, 2011
- A Research Agenda to Underpin Malaria EradicationPLoS Medicine, 2011
- Impact of national malaria control scale-up programmes in Africa: magnitude and attribution of effectsMalaria Journal, 2010
- Evaluation of the Safety and Immunogenicity of the RTS,S/AS01EMalaria Candidate Vaccine When Integrated in the Expanded Program of ImmunizationThe Journal of Infectious Diseases, 2010
- Changes in the burden of malaria in sub-Saharan AfricaThe Lancet Infectious Diseases, 2010
- Development of the RTS,S/AS malaria candidate vaccineVaccine, 2009
- Safety and Immunogenicity of RTS,S/AS02D Malaria Vaccine in InfantsThe New England Journal of Medicine, 2008
- Efficacy of RTS,S/AS01E Vaccine against Malaria in Children 5 to 17 Months of AgeThe New England Journal of Medicine, 2008
- Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trialThe Lancet, 2007
- Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trialThe Lancet, 2004